RxDoctor Payments Data

Payal Suthar, DO

Rheumatology · Duluth, GANPI 1679702781

Payments from drug & device makers

$2,142in general payments, 2019–2025

Across 99 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$629
  • Johnson & Johnson$318
  • Amgen$316
  • Novartis$233
  • AstraZeneca$144
  • Invivyd Inc$90
  • plus $412 from 12 others

What the payments were for

  • Food & beverage$2,04395%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,142 in reported general payments places this provider in the 30th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$6,758
Medicare patients
13
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Amjevita(Cf) AutoinjectorAdalimumab-Atto237$270,854
Enbrel SureclickEtanercept36$220,078
XeljanzTofacitinib Citrate51$139,832
OtezlaApremilast12$53,136
Hydroxychloroquine Sulfate235$7,655
MethotrexateMethotrexate Sodium293$4,891
Leflunomide148$3,799
Mycophenolate Mofetil50$3,798
Prednisone278$2,442
Febuxostat13$664
Alendronate Sodium76$547
Colchicine13$416
Gabapentin25$399
Allopurinol36$359
Azathioprine11$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$316$53,13612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Duluth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →